XKRX
003090
Market cap491mUSD
Oct 08, Last price
15,690.00KRW
1D
-0.06%
1Q
-7.87%
Jan 2017
78.09%
Name
Daewoong Co Ltd
Chart & performance
P/E
3.77
P/S
0.32
EPS
4,164.51
Div yield, %
1.27%
Shrs. gr., 5y
6.73%
Rev. gr., 5y
8.82%
Revenues
2.07t
+6.80%
Net income
175.06b
+202.43%
CFO
257.58b
+58.62%
Dividend
Dec 29, 2025200 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Established in 1961, the firm transitioned its name from Daewoong Pharmaceutical Co., Ltd. to its current designation, Daewoong Co., Ltd., in 2002. Its corporate headquarters are located in Seongnam-si, South Korea.
Key people
President, Chief Executive Officer, Director · since 2023
Gi Ho Song
Vice President, Director · since 2023
Wu Bang Jeon
Internal Auditor · since 2021
Yin Hyeok Choi
Non-Executive Independent Director · since 2023
Non-Executive Independent Director · since 2022
Hun Seok Lee
Non-Executive Independent Director · since 2022
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||